Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

An Embarrassment of Riches in Oncology With Wayward Decision Support: A Recipe for Disaster?

August 15th 2024

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Ongoing Research Aims to Unveil the Optimal Use of Neoadjuvant and Adjuvant Therapies in TNBC

August 15th 2024

Linda T. Vahdat, MD, discusses investigations of ADCs and targeted agents in patients with TNBC and residual disease following chemoimmunotherapy.

Dr Kalinsky on Unmet Needs and Findings from RxPONDER in HR+/HER2– Breast Cancer

August 15th 2024

Kevin Kalinsky, MD, MS, discusses AMH levels and responses in premenopausal HR+/HER2–, node-positive breast cancer.

Dr Mouabbi on Challenges Diagnosing and Managing Invasive Lobular Carcinoma

August 14th 2024

Jason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma

FDA Grants Fast Track Status to AC699 for ER+/HER2–, ESR1-Mutated Breast Cancer

August 14th 2024

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

Dr Feldman on the Prevention and Management of Breast Cancer–Related Lymphedema

August 14th 2024

Sheldon Feldman, MD, discusses prevention and management strategies for breast cancer–related lymphedema.

Dr Thompson on the Necessity of Surgery and Radiation Therapy in Early-Stage Breast Cancer

August 14th 2024

Alastair Thompson, BSc, MBChB, MD, FRCS, discusses ongoing challenges in determining the optimal treatment strategy for patients with early-stage breast cancer.

Dr Yee on Neoadjuvant Datopotamab Deruxtecan in High-Risk, Early-Stage Breast Cancer

August 13th 2024

Douglas Yee, MD, discusses neoadjuvant datopotamab deruxtecan in early-stage breast cancer

Emerging ADCs and Immunotherapy Shake Up Triple-Negative Breast Cancer Management

August 13th 2024

Linda T. Vahdat, MD, discusses the use of ADCs in metastatic TNBC and how neoadjuvant immunotherapy performs in patients with early-stage TNBC.

Dr Llombart-Cussac on the Implications of Prophylaxis for Neutropenia and Diarrhea in Advanced Breast Cancer

August 13th 2024

Antonio Llombart-Cussac, MD, PhD, on the implications of prophylaxis for sacituzumab govitecan–related neutropenia and diarrhea in advanced breast cancer.

Rhenium Obisbemeda Demonstrates Safety and Feasibility in Leptomeningeal Metastases

August 12th 2024

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

RLY-2608 Uses PI3Kα Mutant–Specific Inhibition to More Safely Treat Breast Cancer and Other Solid Tumors

August 12th 2024

Experts provide insights on the first-in-human phase 1 ReDiscovertrial trial, evaluating the mutant-selective PI3Kα inhibitor RLY-2608, which is currently enrolling patients.

Dealing With Progression in HR+/HER2– mBC: Could a CDK4/6 Inhibitor Swap be the Solution?

August 11th 2024

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Dr Mukhtar on Recurrence Risk in Invasive Lobular Carcinoma

August 9th 2024

Rita Mukhtar, MD, discusses the risk of disease recurrence in patients with invasive lobular carcinoma.

Dr Maxwell on Cancer Risk for Males Carrying Germline BRCA Mutations

August 9th 2024

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

RPS-Optimized Checkpoint Inhibition Bolsters pCR in Patients With Select Rare Breast Cancers

August 9th 2024

High pCR rates were observed for patients with uncommon breast cancer subtypes who received response-predictive subtype–optimized therapy.

Dr Lynce on Ongoing Trials Evaluating Novel Combinations in Inflammatory Breast Cancer

August 9th 2024

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Treatment After Progression on CDK4/6 Inhibitors Requires Careful Consideration in HR+/HER2– mBC

August 8th 2024

Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.

Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBC

August 7th 2024

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

August 6th 2024

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.